Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Lupus Nephritis Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Lupus Nephritis Overview | 10 | 1 |
| Pipeline Products for Lupus Nephritis Comparative Analysis | 11 | 1 |
| Lupus Nephritis Therapeutics under Development by Companies | 12 | 2 |
| Lupus Nephritis Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
| Lupus Nephritis Pipeline Products Glance | 15 | 3 |
| Late Stage Products | 15 | 1 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Lupus Nephritis Products under Development by Companies | 18 | 2 |
| Lupus Nephritis Products under Investigation by Universities/Institutes | 20 | 1 |
| Lupus Nephritis Companies Involved in Therapeutics Development | 21 | 19 |
| AbbVie Inc | 21 | 1 |
| Asahi Kasei Pharma Corp. | 22 | 1 |
| Astellas Pharma Inc. | 23 | 1 |
| Aurinia Pharmaceuticals Inc | 24 | 1 |
| Azano Pharmaceuticals Inc. | 25 | 1 |
| Boehringer Ingelheim GmbH | 26 | 1 |
| Bristol-Myers Squibb Company | 27 | 1 |
| Deltanoid Pharmaceuticals Inc. | 28 | 1 |
| F. Hoffmann-La Roche Ltd. | 29 | 1 |
| GlaxoSmithKline Plc | 30 | 1 |
| HanAll Biopharma Co., Ltd. | 31 | 1 |
| Invion Limited | 32 | 1 |
| KPI Therapeutics, Inc. | 33 | 1 |
| MedImmune, LLC | 34 | 1 |
| Omeros Corporation | 35 | 1 |
| Ra Pharmaceuticals, Inc. | 36 | 1 |
| Resolve Therapeutics, LLC | 37 | 1 |
| Takeda Pharmaceutical Company Limited | 38 | 1 |
| TxCell SA | 39 | 1 |
| Lupus Nephritis Therapeutics Assessment | 40 | 9 |
| Assessment by Monotherapy Products | 40 | 1 |
| Assessment by Target | 41 | 2 |
| Assessment by Mechanism of Action | 43 | 2 |
| Assessment by Route of Administration | 45 | 2 |
| Assessment by Molecule Type | 47 | 2 |
| Drug Profiles | 49 | 75 |
| abatacept Drug Profile | 49 | 5 |
| anifrolumab Drug Profile | 54 | 2 |
| belimumab Drug Profile | 56 | 6 |
| BI-655064 Drug Profile | 62 | 2 |
| BMS-986147 Drug Profile | 64 | 1 |
| dalazatide Drug Profile | 65 | 4 |
| DP-001 Drug Profile | 69 | 1 |
| Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis Drug Profile | 70 | 1 |
| ENTX-DN Drug Profile | 71 | 1 |
| HL-161 Drug Profile | 72 | 1 |
| INV-103 Drug Profile | 73 | 3 |
| ixazomib citrate Drug Profile | 76 | 9 |
| mizoribine Drug Profile | 85 | 1 |
| Monoclonal Antibody for Lupus Nephritis Drug Profile | 86 | 1 |
| obinutuzumab Drug Profile | 87 | 7 |
| OMS-721 Drug Profile | 94 | 5 |
| P-Dex Drug Profile | 99 | 1 |
| RA-101495 Drug Profile | 100 | 2 |
| RO-5461111 Drug Profile | 102 | 1 |
| RSLV-145 Drug Profile | 103 | 1 |
| Stem Cell Therapy for Autoimmune Diseases Drug Profile | 104 | 2 |
| Synthetic Peptide to Inhibit Complement C5 for Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome and Autoimmune Disorders Drug Profile | 106 | 1 |
| venetoclax Drug Profile | 107 | 9 |
| voclosporin Drug Profile | 116 | 7 |
| Y-175L Drug Profile | 123 | 1 |
| Lupus Nephritis Dormant Projects | 124 | 2 |
| Lupus Nephritis Discontinued Products | 126 | 1 |
| Lupus Nephritis Product Development Milestones | 127 | 14 |
| Featured News &Press Releases | 127 | 1 |
| Aug 15, 2016: Aurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus Nephritis | 127 | 2 |
| Jun 28, 2016: Aurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN) | 129 | 1 |
| Jun 10, 2016: Alliance for Children Therapeutics Presents Dalazatide Data Demonstrating Positive Response in Lupus | 130 | 1 |
| May 23, 2016: KPI Therapeutics to Present Updated Dalazatide Study Data in Lupus | 131 | 1 |
| May 12, 2016: Aurinia Announces Presentations at the European Renal Association European Dialysis and Transplant Association Meeting | 131 | 1 |
| May 09, 2016: Aurinia Initiates First Clinical Study of Voclosporin for Japan | 132 | 1 |
| Apr 20, 2016: Patient Dosing Initiated for OMS721 Phase 2 Program in Renal Diseases | 133 | 1 |
| Mar 29, 2016: Aurinia Announces Result from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis Study to Continue as Planned | 134 | 1 |
| Mar 02, 2016: Aurina Receives FDA Fast Track Designation for Voclosporin for the Treatment of Lupus Nephritis | 135 | 1 |
| Feb 08, 2016: Aurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis | 135 | 1 |
| Feb 02, 2016: Deltanoid Pharmaceuticals Announces Appointment of Douglas Jermasek as Chief Executive Officer | 136 | 1 |
| Jan 19, 2016: Aurinia Announces Completion of Patient Enrollment in Its Phase 2B AURA-LV Study in Lupus Nephritis | 137 | 1 |
| Dec 03, 2015: Ocata s Hemangio-derived Mesenchymal Cells Preserve Kidney Function and Extend Lifespan in Preclinical Model of Lupus Nephritis | 138 | 1 |
| Nov 24, 2015: Aurinia Pharmaceuticals Announces Outcome from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis Study to Continue as Planned | 139 | 1 |
| Nov 10, 2015: Kineta, Seattle Children s Research Institute Present New Data Demonstrating Positive, Predictive Responses to Dalazatide In Lupus | 139 | 2 |
| Appendix | 141 | 2 |
| Methodology | 141 | 1 |
| Coverage | 141 | 1 |
| Secondary Research | 141 | 1 |
| Primary Research | 141 | 1 |
| Expert Panel Validation | 141 | 1 |
| Contact Us | 141 | 1 |
| Disclaimer | 142 | 1 |